BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 1, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2017

View Archived Issues

Medlab receives ethics approvals for trials of two cannabis-based medicines

Read More

Pfizer initiates phase I study of group B Streptococcus vaccine PF-06760805

Read More

Unum Therapeutics announces active IND for ACTR-707

Read More

NIAID grants support development of vaccines for Zika virus and river blindness

Read More

Biocad's BCD-055 demonstrates equivalence to infliximab in clinical trials

Read More

twoXAR's TXR-411 shows promise in mouse model of type 2 diabetes

Read More

Phase Ib results for infigratinib plus imatinib in patients with advanced GIST presented

Read More

Phase I/II results for cabiralizumab monotherapy in patients with tenosynovial giant cell tumor

Read More

Enrollment to begin in phase I/II trial of Ceplene for the treatment of CMML

Read More

Heidelberg Pharma and Takeda sign exclusive multitarget research agreement

Read More

Phase II results show beneficial effects of NT-501 in patients with macular telangiectasia type 2

Read More

Phase II study of glepaglutide in patients with short bowel syndrome meets primary endpoint

Read More

AbbVie's lutikizumab fails primary endpoint in a phase IIa trial for hand OA

Read More

SerImmune enters research and development collaboration with Merck & Co.

Read More

NCATS grants to fund use of Emulate's Human Emulation System on International Space Station

Read More

FDA approves Mydayis for adolescents and adults with ADHD

Read More

eFFECTOR enters collaboration to study EFT-508 with avelumab in colorectal cancer

Read More

Almac Discovery collaborates with Debiopharm on Wee-1 kinase inhibitor program

Read More

NINDS grant supports development of BlackThorn Therapeutics' KOR antagonist program

Read More

Nimbus Apollo presents acetyl-CoA carboxylase inhibitors

Read More

Icagen partners with Omdana on disorders related to tissue homeostasis and vascular remodeling

Read More

Shenzhen Targetrx Biotechnology discloses novel tyrosine kinase inhibitors

Read More

Seattle Genetics submits supplemental BLA for Adcetris in CTCL

Read More

Glenmark licenses small-molecule oncology compound from APC Therapeutics

Read More

A novel orally active ACC2-selective inhibitor improves glucose homeostasis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 31, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing